Horizon Pharma's (HZNP) FY16 Revenue Guidance Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Actimmune and Friedreich's Ataxia Could Help Horizon Pharma (HZNP) Post Upside, Mizuho Says; PT to $34
November 10, 2015 6:57 AM ESTHorizon Pharma (NASDAQ: HZNP) reported 3Q:15 revenue of $226.5M vs. consensus of $193.2M. Adjusted EPS of $0.70 also beat the consensus number of $0.41. The beat was driven by strong product demand (volumes) across all of the company's brands, coupled with lower than expected SG&A expense and... More
